Back
Erasca, Inc. 10K Form
Sell
42
ERAS
Erasca, Inc.
Last Price:
$13.37
Seasonality Move:
-13.72%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive ERAS News And Ratings
See the #1 stock for the next 7 days that we like better than ERAS
ERAS Financial Statistics
Sales & Book Value
| Annual Sales: | $0 |
|---|---|
| Cash Flow: | $-21.7M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $1.14 |
| Price / Book: | 12.86 |
Profitability
| EPS (TTM): | -0.43930 |
|---|---|
| Net Income (TTM): | $-124.5M |
| Gross Margin: | $-3.1M |
| Return on Equity: | -33.33% |
| Return on Assets: | -27.71% |
Erasca, Inc. Earnings Forecast
Key Erasca, Inc. Financial Ratios
-
Per Share Earnings over the last 7 years have been positive in 4 years.
Erasca, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | ERAS |
| Website: | erasca.com |
Debt
| Debt-to-Equity Ratio: | 0.15 |
|---|---|
| Current Ratio: | 10.04 |
| Quick Ratio: | 9.68 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
ERAS Technical Analysis vs Fundamental Analysis
Sell
42
Erasca, Inc. (ERAS)
is a Sell
Is Erasca, Inc. a Buy or a Sell?
-
Erasca, Inc. stock is rated a SellThe current Erasca, Inc. [ERAS] share price is $13.62. The Score for ERAS is 42, which is 16% below its historic median score of 50, and infers higher risk than normal.